Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Stock Market Today: The S&P 500 Reclaims the 6K Level

Investors see Scott Bessent as a safe shepherd of the economy as the president-elect burnishes his "Tariff Man" reputation.

Kiplinger

Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs

The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis.

Benzinga

Novo Nordisk Foundation CEO dismisses ‘Nokia risk’ to Denmark’s economy

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion people living with obesity.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?

Robert F. Kennedy Jr.'s potential appointment to HHS has spooked Eli Lilly stock and stocks tied to popular weight-loss drugs.

Investors Business Daily

Wegovy on sale in China, cheaper than US

The medication is currently available in 16 other countries

Salon

Weight-Loss Drugmakers Press Companies To Cover Cost Of Treatment

The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.

International Business Times

Buy This Pharma Stock to Bet on the Next Blockbuster Weight-Loss Drug

A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1 drugs, and amylin-based drugs are next. Novo Nordisk's compound, Cagrilintide, will be combined with semaglutide in its…

Barchart

Read news from The Economist, FT, and more,
with one subscription

Drugmakers see stocks tank after RFK Jr is nominated to oversee health department

JP Morgan Chase analysts say they’re ‘not surprised’ sector has come ‘under pressure’ since Kennedy’s nomination

The Independent UK

Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review

The stock market surged to highs on Donald Trump's election win. A Fed rate cut and a slew of big earnings reports filled out a busy week.

Investors Business Daily

Novo Nordisk Slumps On Tightened Outlook As Wegovy Beats, But Ozempic Lags

Novo Nordisk stock fell Wednesday after the drugmaker's weight-loss drug beat forecasts, but Ozempic sales missed.

Investors Business Daily

Obesity Drug Maker Novo Nordisk Posts Strong Profit

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by production constraints.

International Business Times

Danish town where Ozempic is made has highest rates of overweight children in Denmark

Novo Nordisk faces a challenge turning around the fortunes of residents in a major Danish manufacturing hub.

Fortune

Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat

Viking Therapeutics reported strong weight loss for higher doses of its experimental obesity drug.

Investors Business Daily

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH

Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.

Evening Standard

Weight loss drugs may cause addiction switching, says award-winning therapist

Labour’s plans to give weight loss drugs to the unemployed may not just fail: it could backfire, therapist Sally Baker explains

The Independent UK

Ozempic, Wegovy considered ‘available’ after more than 2 years in shortage

Demand for the popular weight loss and diabetes drugs has spiked dramatically in recent years

Evening Standard

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections

As drugs emerge as vital to the Government’s anti-obesity strategy, BBC Panorama is shedding light on the pharmaceuticals industry behind them

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Pumping the unemployed with weight-loss drugs echoes Victorian attitudes to the poor

Shifting blame to the victims of economic policy is an old trick by politicians. Now they’re using obesity to tackle joblessness

Cycling News

Declan Irvine uses 'pioneer' eating skills to manage diabetes and battle Life Time Grand Prix riders at Big Sugar Gravel

Team Novo Nordisk rider among a trio of top Australians in elite men's field

The Guardian - UK

Weight-loss drug firm accused of prioritising profits after halting insulin pen production

Novo Nordisk’s decision will force people in developing countries to use outdated glass vials and syringes, warn campaigners

The Conversation

Glucose monitors for diabetes have finally been funded – but a chronic workforce shortage will limit the benefits

Pharmac’s decision to fund continuous glucose monitors and automated insulin delivery systems for the approximately 18,000 people who currently live with type 1 diabetes in Aotearoa New Zealand is good news.

Investors Business Daily

How To Invest: Biotechs Can Make Huge Gains But Have Unique Risks

In some cases, biotechs go public without having even a single product on the market.

Fortune

Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis

'Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff Sonnenfeld and Steven Tian.

The Conversation

Buyer beware: Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease.

1 … 4 5 6 7

People

Lars Fruergaard Jørgensen

12 stories

Alan Crawford

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.